Proteomics and Down syndrome screening: a validation study
Prenatal Diagnosis2010Vol. 30(11), pp. 1039–1043
Citations Over TimeTop 1% of 2010 papers
Maria P. H. Koster, Jeroen L. A. Pennings, Sandra Imholz, Wendy Rodenburg, Gerard H. A. Visser, Annemieke de Vries, Peter C. J. I. Schielen
Abstract
Validation of previously identified biomarkers only confirmed EGF for further consideration as a DS screening marker. This underlines the importance of validating biomarkers; in this study, limiting the range of plausible biomarkers to only one suitable biomarker.
Related Papers
- → Recurrences of free trisomy 21: analysis of data from the National Down Syndrome Cytogenetic Register(2005)103 cited
- → Decreasing mosaicism in Down's syndrome(1980)28 cited
- Robertsonian Translocations t(21q;21q) and t(14q;21q) in Down Syndrome(2017)
- Analysis of Prenatal Sonography in Screening Down Syndrome and Trisomy 18(2010)
- Analysis of prenatal sonography in screening Down syndrome and trisomy 18(2004)